| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD8-M82E3 | Mouse | Biotinylated Mouse CD28 Protein, His,Avitag™ |  |
|
|
| CD8-H82E5 | Human / Cynomolgus / Rhesus macaque | Biotinylated Human / Cynomolgus / Rhesus macaque CD28 Protein, His,Avitag™ |  |
|
|
| CD8-H52Hc | Human / Cynomolgus / Rhesus macaque | Human / Cynomolgus / Rhesus macaque CD28 Protein, His Tag (MALS verified) |  |
|
|
| CD8-H525a | Human / Cynomolgus / Rhesus macaque | Human / Cynomolgus / Rhesus macaque CD28 Protein, Fc Tag (HPLC-verified) |  |
|
|
| CD8-H52A5 | Human / Cynomolgus / Rhesus macaque | Human / Cynomolgus / Rhesus macaque CD28 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD8-H82F2 | Human / Cynomolgus / Rhesus macaque | Biotinylated Human / Cynomolgus / Rhesus macaque CD28 Protein, Fc,Avitag™ |  |
|
|
| CD8-M5257 | Mouse | Mouse CD28 Protein, Fc Tag |  |
|
|
| CD8-M52H6 | Mouse | Mouse CD28 Protein, His Tag |  |
|
|
Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (HPLC-verified) (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 5.29 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (HPLC-verified) (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Nunès, J A., et al., 1996, J. Biol. Chem. (UNITED STATES) 271 (3): 1591–8.
Ellis, J H., et al., 2000, J. Immunol. (UNITED STATES) 164 (11): 5805–14.
Midtvedt K, et al., 2003, Clinical transplantation 17 (1): 69–74.
McMichael, A. J., P.C.L. Beverly, et al., 1987, Oxford University Press. New York.
Knapp, W., B. Dorken, et al., 1989, Oxford University Press. New York.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Phase Not Specified | Wuhan Bio-Raid Biotechnology | hematological malignancies | Details | |
| Abatacept (Orban Biotech) | Phase Ⅱ | The National Institute of Diabetes and Digestive and Kidney Diseases, Orban Biotech | Type 1 diabetes | Details | |
| FPT-155 | CD80-Fc; FPT-155 | Phase Ⅰ | Five Prime Therapeutics | Solid tumours | Details |
| Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase Ⅰ | City of Hope National Medical Center | Non-Hodgkin's lymphoma (NHL) | Details | |
| Recombinant CD28 (CytoMed) | Phase Not Specified | CytoMed | Autoimmune diseases, Rheumatoid arthritis (RA), Allergic diseases, Prophylaxis of organ rejection | Details | |
| TGN-1412 | TGN-1412 | Phase Ⅰ | TeGenero | Cancer | Details |
| Lulizumab pegol | BMS-931699; Lulizumab | Phase Ⅱ | Bristol-Myers Squibb | Sjoegren's syndrome, Systemic lupus erythematosus | Details |
| Anti-CD28/anti-HMV-MAA bispecific antibody (Eberhard-Karls-Universitaet Tuebingen) | rM28; r28M | Phase Ⅱ | Eberhard-Karls Universitaet Tuebingen | Cancer | Details |
| ALPN-101 | ALPN-101 | Phase Ⅰ | Alpine Immune Sciences | Autoimmune diseases, Graft versus host disease, Inflammation | Details |
| ALPN-202 | ALPN-202 | Phase Ⅰ | Alpine Immune Sciences | Cancer | Details |
| B7-2/GM-CSF cancer gene therapy | CIT | Phase Ⅰ | Radient | Solid tumours | Details |
| FR-104 | FR-104; JNJ-3133,FR104; JNJ3133 | Phase Ⅱ | Effimune, Janssen, Biomedical Primate Research Center, OSE Immunotherapeutics | Transplant rejection, Rheumatoid arthritis (RA) | Details |
| Theralizumab | TAB-08; TABO-8 | Phase Ⅱ | TheraMAB | Plaque psoriasis, Systemic lupus erythematosus | Details |
| Membrane bound ligand T-SIGn virus | NG-348 | Phase Ⅰ | PsiOxus Therapeutics, Bristol-Myers Squibb | Solid tumours | Details |
| Reltecimod | AB-103; P2-TA | Phase Ⅲ | Atox Bio | Acute kidney injury, Soft tissue infections, Peritonitis | Details |
This web search service is supported by Google Inc.
A-Z